A Controlled, Randomized, Parallel , Multi-Centre Feasibility Study of the Oral Direct Thrombin Inhibitor, AZD0837, Given as ER Formulation, in the Prevention of Stroke and Systolic Embolic Events in Patients With Atrial Fibrillation, Who Are Appropriate for But Unable/Unwilling to Take VKA [vitamin K antagonist] Therapy.

Trial Profile

A Controlled, Randomized, Parallel , Multi-Centre Feasibility Study of the Oral Direct Thrombin Inhibitor, AZD0837, Given as ER Formulation, in the Prevention of Stroke and Systolic Embolic Events in Patients With Atrial Fibrillation, Who Are Appropriate for But Unable/Unwilling to Take VKA [vitamin K antagonist] Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2012

At a glance

  • Drugs AZD 0837 (Primary) ; Aspirin; Clopidogrel
  • Indications Embolism; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Nov 2009 Results were presented at the 82nd Annual Scientific Sessions of the American Heart Association.
    • 02 Jul 2008 The expected completion date for this trial has been extended from May 2008 to Dec 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top